2024
An update on the management of axial spondyloarthritis for sports medicine professionals
Danve A, Magrey M, Deodhar A. An update on the management of axial spondyloarthritis for sports medicine professionals. BMC Sports Science, Medicine And Rehabilitation 2024, 16: 211. PMID: 39375817, PMCID: PMC11460014, DOI: 10.1186/s13102-024-00998-z.Peer-Reviewed Original ResearchNonsteroidal anti-inflammatory drugsBiologic disease-modifying antirheumatic drugsMedicine practitionersImprove health-related quality of lifeSuspected axSpAHealth-related quality of lifeImprove health-related qualitySports medicine professionalsSports medicine practitionersChronic back painManagement of axial spondyloarthritisReferral of patientsDisease-modifying antirheumatic drugsCurrent treatment possibilitiesInadequately controlled diseaseQuality of lifeTargeted synthetic (ts) DMARDsFirst-line treatmentHeterogeneous clinical featuresLong-term outcomesDisease activity measuresPhysical therapyBack painChronic inflammatory diseaseMedicine professionalsIxekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Danve A, Vadhariya A, Lisse J, Cholayil A, Bansal N, Bello N, Bakewell C. Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study. Rheumatology And Therapy 2024, 11: 1333-1345. PMID: 39162898, PMCID: PMC11422398, DOI: 10.1007/s40744-024-00710-0.Peer-Reviewed Original ResearchHealth care resource utilizationFollow-up periodTumor necrosis factor-alpha inhibitorsTreatment patternsAxial spondyloarthritisPre-indexMethodsThis retrospective cohort studyBiologic-experienced patientsCharlson Comorbidity Index scoreRetrospective cohort studyClaims database studyIntroductionReal-world dataAssessed patient demographicsComorbidity Index scoreHigher comorbidity burdenProportion of daysBiologic-experiencedPatient demographicsClinical characteristicsIxekizumabIndex dateCohort studyPharmacy enrollmentEmergency room visitsAxSpAIs yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areasHow to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice
Kumthekar A, Sanghavi N, Natu A, Danve A. How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice. Current Rheumatology Reports 2024, 26: 170-177. PMID: 38372873, DOI: 10.1007/s11926-024-01141-0.Peer-Reviewed Original ResearchBath Ankylosing Spondylitis Disease Activity IndexElectronic patient-reported outcome measuresDisease activity measuresAssessment of disease activityC-reactive proteinDisease activityAxial spondyloarthritisDisease activity of axial spondyloarthritisClinical practicePatient-Reported Outcomes Measurement Information SystemOutcomes Measurement Information SystemOutcome measuresAnkylosing Spondylitis Disease Activity IndexIntegration of electronic health recordsMonitoring of disease activitySymptoms of axSpATreatment of axSpA.Patient-reported outcome measuresMeasurement Information SystemAxSpA disease activityElectronic health recordsMonitoring disease activityDisease activity indexLong-term outcomesPatient-reported data
2023
Impact d’un score extrême d’activité de la maladie (BASDAI) et/ou d’enthésites (MASES) à l’inclusion sur la réponse au traitement par upadacitinib chez des patients atteints de spondyloarthrite axiale
Dougados M, Bulbin D, Jones H, Gao T, Shmagel A, Poznanski T, Danve A, Gaffney K. Impact d’un score extrême d’activité de la maladie (BASDAI) et/ou d’enthésites (MASES) à l’inclusion sur la réponse au traitement par upadacitinib chez des patients atteints de spondyloarthrite axiale. Revue Du Rhumatisme 2023, 90: a163. DOI: 10.1016/j.rhum.2023.10.250.Peer-Reviewed Original ResearchImplementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter L, Danve A. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care & Research 2023 PMID: 37382043, DOI: 10.1002/acr.25181.Peer-Reviewed Original ResearchBest practice advisoryHepatitis B virusAutoimmune rheumatic diseasesBPA implementationSynthetic disease-modifying antirheumatic drugsDisease-modifying antirheumatic drugsHepatitis C virus infectionHepatitis B surface antigenC virus infectionUse of biologicsB surface antigenQuality improvement initiativesElectronic health recordsEligible patientsAntirheumatic drugsRheumatic diseasesRheumatology practiceSociety guidelinesB virusPractice advisoryComputerized decision support systemVirus infectionRoutine screeningPatient screeningPatients
2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitorsEfficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis
Deodhar A, Chakravarty SD, Shiff NJ, Lo KH, Xu S, Hsia EC, Danve A, Reveille JD. Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis. JCR Journal Of Clinical Rheumatology 2022, 28: 420-423. PMID: 35649533, PMCID: PMC9704810, DOI: 10.1097/rhu.0000000000001857.Peer-Reviewed Original ResearchRheumatic Disorders
Alexander S, Duddy C, Danve A, Sehra S. Rheumatic Disorders. 2022, 557-566. DOI: 10.1007/978-3-030-92042-5_55.ChaptersNoninflammatory causesJoint painMuscle painRheumatoid arthritisInflammatory bowel diseaseInflammatory causesInflammatory arthritidesPsoriatic arthritisReactive arthritisBowel diseaseCommon presentationRheumatic disordersLaboratory presentationCommon causeArthritisPainMultiple specialtiesCausePresentationArthritidesFibromyalgiaSpondylitisOsteoarthritisGoutDiseaseTreatment of axial spondyloarthritis: an update
Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nature Reviews Rheumatology 2022, 18: 205-216. PMID: 35273385, DOI: 10.1038/s41584-022-00761-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Update on gout management: what is old and what is new
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current Opinion In Rheumatology 2021, 34: 118-124. PMID: 34907116, PMCID: PMC8799507, DOI: 10.1097/bor.0000000000000861.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyRisk factorsAdjunctive management strategiesUrate-lowering efficacyChronic kidney diseaseUse of allopurinolAllopurinol hypersensitivity syndromeManagement of hyperuricemiaCrystal-Associated Disease NetworkPopulation attributable riskEvidence-based recommendationsComprehensive evidence-based recommendationsNew drug therapiesGout guidelinesCause mortalityHypersensitivity syndromeCardiovascular riskGout flaresGout managementKidney diseaseDrug therapyFlare managementAttributable riskDietary factorsSerum urateRole of diet in hyperuricemia and gout
Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Practice & Research Clinical Rheumatology 2021, 35: 101723. PMID: 34802900, PMCID: PMC8678356, DOI: 10.1016/j.berh.2021.101723.Peer-Reviewed Original ResearchConceptsDietary factorsLong-term clinical courseWeight lossMainstay of therapyUrate-lowering therapySerum urate levelsRole of dietLow purine dietTreatment of goutGout outcomesInflammatory arthritisClinical courseDefinitive managementDietary ApproachesGout flaresUrate levelsGlobal burdenGoutHyperuricemiaIndividual foodsHigh fructose corn syrupCertain foodsLimited evidenceVitamin CCommon form
2020
Rising Global Burden of Gout: Time to Act
Danve A, Neogi T. Rising Global Burden of Gout: Time to Act. Arthritis & Rheumatology 2020, 72: 1786-1788. PMID: 33150696, PMCID: PMC7644950, DOI: 10.1002/art.41453.Peer-Reviewed Original ResearchThe effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoLManaging rheumatic diseases during COVID-19
Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clinical Rheumatology 2020, 39: 3245-3254. PMID: 32895747, PMCID: PMC7476772, DOI: 10.1007/s10067-020-05387-8.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesRheumatic diseasesImmunosuppressive agentsRheumatology practiceCOVID-19Multisystem autoimmune rheumatic diseaseLong-term complicationsCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionDisease 2019 pandemicMode of spreadImmunosuppressant managementImmunosuppressant medicationsViral illnessOrgan failureClinical featuresAutoimmune diseasesSerious infectionsTreatment optionsEffective vaccineImmune systemMedicationsDiseasePatientsAssessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort
Rich-Garg N, Danve A, Choi D, Vakil-Gilani K, Akkoc N, Azevedo V, Russell A, Sharma A, Cush J, Curtis JR, Deodhar A. Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort. Clinical Rheumatology 2020, 40: 949-954. PMID: 32797363, DOI: 10.1007/s10067-020-05308-9.Peer-Reviewed Original ResearchRecognizing Axial Spondyloarthritis: A Guide for Primary Care
Magrey MN, Danve AS, Ermann J, Walsh JA. Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clinic Proceedings 2020, 95: 2499-2508. PMID: 32736944, DOI: 10.1016/j.mayocp.2020.02.007.Peer-Reviewed Original ResearchConceptsInflammatory back painBack painAxial spondyloarthritisHuman leukocyte antigen-B27 positivityChronic low back painNonsteroidal anti-inflammatory drugsExtra-articular manifestationsAge 45 yearsChronic back painLow back painAnti-inflammatory drugsEnglish-language articlesButtock painMorning stiffnessPeripheral arthritisSymptom onsetB27 positivityInsidious onsetAxial SpASpA featuresPrimary careEarly recognitionActive axSpAEffective therapyFamily history2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology 2020, 72: 879-895. PMID: 32390306, DOI: 10.1002/art.41247.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research 2020, 72: 744-760. PMID: 32391934, PMCID: PMC10563586, DOI: 10.1002/acr.24180.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs
2019
Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
Department of Internal Medicine Y, Sutaria R, Patel P, Department of Rheumatology Y, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal Of Rheumatology 2019, 6: 153-154. PMID: 30986169, PMCID: PMC6668642, DOI: 10.5152/eurjrheum.2019.18159.Peer-Reviewed Original ResearchMetastatic melanomaCheckpoint inhibitorsMyasthenia gravisAutoimmune myositisCombination of ipilimumabCytotoxic T lymphocytesCombination therapyT lymphocytesImmune responseAdverse effectsMelanomaNumerous immuneIpilimumabNivolumabNovel optionGravisMyositisDeactivation signalsInhibitorsMalignancyTherapyTumors